BioPharm International, October 2011 - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

BioPharm International, October 2011
Features
Survey Examines Trends in the Outsourcing Relationship
By Eric S. Langer
The BioPlan Associates 8th annual survey identifies key outsourcing concerns of sponsor companies.
Trends in Biologics Outsourcing
By Amy Ritter, PhD
A Q&A with Rick Hancock, president of Althea Technologies. This article contains bonus online material.
Contract Services Spending: Who's Spending What, and Where?
By Kate Hammeke
A survey provides insight into drug companies' plans for spending on outsourced services. This article contains bonus online material.
Characterization of TrypZean: a Plant-Based Alternative to Bovine-Derived Trypsin (Peer-Reviewed)
By Kevin Ray , Pegah R. Jalili
An in-depth characterization of maize-derived trypsin revealed an unusual nonconsensus N-linked glycosylation.
Perspectives in MicroRNA Therapeutics
By Kevin Steffy , Charles Allerson , Balkrishen Bhat
The authors provide insight into microRNA biology, and the simplicity of anti-miR oligonucleotide drug delivery.
Guest Editorial
Education and Training in Biopharmaceutical Development
By Philip R. Mayer, PhD
It is important for all of us to be well versed in the new sciences that impact the development of protein therapeutics.
Regulatory Beat
Global Health Challenges Spur Vaccine Development
By Jill Wechsler
Manufacturers fund research and reduce prices to tackle diseases around the world.
Burrill on Biotech
Volatile Markets Take a Toll on Life-Sciences Initial Public Offerings
By G. Steven Burrill
Volatile Markets Take a Toll on Life-Sciences Initial Public Offerings
Perspectives on Outsourcing
Preparing for the Last War
By Jim Miller
CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.
Final Word
How to Choose the Right CMO
By Peter Soelkner
Knowing in advance what you need can make a huge difference in a sponsor company's success.

ADVERTISEMENT

ADVERTISEMENT

Click here